Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sotuletinib (BLZ945) dihydrochloride is an orally administered, blood-brain barrier-permeable inhibitor specifically targeting CSF1-R with an IC50 of 1 nM. It promotes apoptosis in tumor cells and significantly restricts tumor growth in murine models, proving useful in cancer and amyotrophic lateral sclerosis (ALS) studies [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Sotuletinib (BLZ945) dihydrochloride is an orally administered, blood-brain barrier-permeable inhibitor specifically targeting CSF1-R with an IC50 of 1 nM. It promotes apoptosis in tumor cells and significantly restricts tumor growth in murine models, proving useful in cancer and amyotrophic lateral sclerosis (ALS) studies [1]. |
Synonyms | BLZ945 dihydrochloride |
Molecular Weight | 471.4 |
Formula | C20H24Cl2N4O3S |
CAS No. | 2222138-40-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sotuletinib dihydrochloride 2222138-40-9 Tyrosine Kinase/Adaptors c-Fms BLZ945 dihydrochloride inhibitor inhibit